AXAxoGen, Inc. AXGN · NASDAQ
$36.17 -2.53% (-$0.94)
- Market cap
- $1.94B
- Enterprise value
- $1.87B
- P/E
- -
- Forward P/E
- 94.6x
- PEG
- -
- P/S
- 7.7x
- P/FCF
- 769.8x
- EV/EBITDA
- -
- ROIC
- -4.6%
- Gross margin
- 74.6%
- Net margin
- -13.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.17
- Free float
- 97.1%
About the company
AxoGen, Inc. (AXGN) is a biotechnology company focused on the development and manufacture of innovative therapeutic products and therapies for peripheral nerve repair. Their products are designed to aid patients with peripheral nerve damage caused by traumatic injuries or surgical procedures. AxoGen specializes in utilizing advanced technologies and biological materials to support nerve cell regeneration and restore nervous system function. The company is a leading player in the field of regenerative medicine and is focused on providing innovative solutions for the treatment of patients with nerve injuries. Shares of AxoGen, Inc. (AXGN) may be attractive to investors seeking opportunities in the biotechnology and regenerative medicine sector.
Sector
Healthcare
Industry
Medical - Devices
CEO
Michael D. Dale
Employees
622
Headquarters
Alachua
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number